Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Meets Primary and Secondary Endpoints in Placebo-Controlled U.S. Phase 2 Clinical Trial for the Treatment of Adult Patients with Rett Syndrome
https://www.anavex.com/anavex-life-...he-treatment-of-adult-patients-with-rett-syn/
- Forums
- ASX - By Stock
- NEU
- ANAVEX MEETS ENDPOINTS PHASE2 RETT
ANAVEX MEETS ENDPOINTS PHASE2 RETT
- There are more pages in this discussion • 166 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$21.22 |
Change
0.450(2.17%) |
Mkt cap ! $2.705B |
Open | High | Low | Value | Volume |
$20.76 | $21.43 | $20.70 | $7.892M | 373.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 596 | $21.22 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$21.26 | 1054 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 3443 | 21.180 |
2 | 1077 | 21.160 |
1 | 1005 | 21.150 |
2 | 5900 | 21.130 |
2 | 1882 | 21.110 |
Price($) | Vol. | No. |
---|---|---|
21.260 | 1054 | 1 |
21.300 | 1270 | 2 |
21.350 | 1077 | 2 |
21.370 | 194 | 1 |
21.430 | 1005 | 1 |
Last trade - 16.10pm 28/03/2024 (20 minute delay) ? |
|
|||||
Last
$21.24 |
  |
Change
0.450 ( 2.73 %) |
|||
Open | High | Low | Volume | ||
$20.76 | $21.42 | $20.73 | 102057 | ||
Last updated 15.59pm 28/03/2024 ? |
Featured News
NEU (ASX) Chart |
The Watchlist
BGD
BARTON GOLD HOLDINGS LIMITED
Alex Scanlon, Managing Director & CEO
Alex Scanlon
Managing Director & CEO
SPONSORED BY The Market Online